Recent decline in prostate cancer incidence in the United States, by age, stage, and Gleason score

Abstract

Prostate cancer incidence is sensitive to screening practices, however the impact of recent screening recommendations from the United States Preventative Services Task Force on prostate cancer incidence by age, stage, race, and Gleason score is unknown. This study described the timing and magnitude of changes in prostate cancer incidence trends in the United States by month of diagnosis, and evaluated trends by age, Gleason score, and stage at diagnosis. We analyzed prostate cancer incidence trends using Surveillance, Epidemiology, and End Results (SEER) program data for men diagnosed with invasive prostate cancer from 2007 through 2012. JoinPoint analysis was used to detect changes in the rate of annual percent change (APC) in prostate cancer incidence for all diagnoses and by age, Gleason score, race, and stage. Prostate cancer incidence declined at an estimated −19.6% APC beginning May 2011. This decline was observed in all age groups. Low‐grade tumors (Gleason score ≤6) showed a steeper decline (−29.1% APC) than high‐grade tumors (Gleason score 8–10: −10.8% APC). Only stage I/II and stage III tumors saw declines (−24.2% and −16.7% APC, respectively). A sharp decline in prostate cancer incidence began before release of the United States Preventative Services Task Force October 2011 draft and May 2012 final screening recommendation. The greatest change occurred with incidence of low‐grade tumors, although there is concern that some high‐grade tumors may now go undetected.

The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA

“…Trends also coincide with the simultaneous publications of the two conflicting results of RCTs of PSA-screening, ERSPC and PLCO, which published their first results in 2009. 29, 62 …”

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

“…1 Over the past several years, the incidence of prostate cancer has declined, likely in part as a result of decreased detection attributed to decreased rates of prostate-specific antigen (PSA) screening. [2][3][4] The decreasing and comparatively low death rate suggests that increased public awareness with earlier detection and treatment has affected mortality from this prevalent cancer.…”

Changes in thyroid cancer incidence, post‐2009 American Thyroid Association guidelines

“…A similar pattern is seen for prostate cancer, for which the introduction of prostate serum antigen (PSA) testing saw a dramatic increase in prostate cancer diagnoses between the late 1980s and early 1990s. Subsequent revisions to the United States Preventive Task Force management guidelines in 2011 recommending against routine PSA testing were followed by a steep concordant decline in the incidence of prostate cancer …”